All stock lists
OmniAb, Inc. (NASDAQ:OABI)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
5.09-0.02 (-0.39%)
Market cap
$740M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 30, 2021
Website
Insider Score
––Not scored
OABI Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
OABI analyst forecast
OABI analyst consensus
Moderate Buy3 ratings
Buy 3 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
OABI 12-month price target
No published price targets in the last 12 months.
OABI ratings mix, last 12 months
Buy Hold Sell
Best analysts covering OABI
- HC Wainwright & Co.29%success rate · -18.5% avg return · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
OABI analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | StoneX | Buy | — | — | Reiterated | 2026-10-07 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-10-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-17 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-07 |
| — | Benchmark | Buy | — | — | Reiterated | 2025-05-12 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-03-27 |
| — | Benchmark | Buy | — | — | Reiterated | 2025-03-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-19 |
| — | Benchmark | Buy | — | — | Reiterated | 2024-11-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-14 |
| — | Benchmark | Buy | — | — | Reiterated | 2024-08-19 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-08-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-12 |
| — | Benchmark | Buy | — | — | Reiterated | 2024-05-14 |
| — | Truist Securities | Buy | — | — | Reiterated | 2024-03-26 |
| — | Benchmark | Buy | — | — | Reiterated | 2024-03-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-21 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-03-21 |
| — | Benchmark | Buy | — | — | Reiterated | 2023-11-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-11 |
| — | Benchmark | Buy | — | — | Reiterated | 2023-05-12 |
| — | Benchmark | Buy | — | — | Reiterated | 2023-04-21 |
| — | Craig-Hallum | Buy | — | — | Reiterated | 2023-04-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-31 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2023-02-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-02-13 |
| — | Truist Securities | Buy | — | — | Reiterated | 2022-12-20 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2022-12-16 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2022-11-29 |
| — | Stifel | Buy | — | — | Reiterated | 2022-11-28 |
OABI earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-04 | -0.08 | -0.11 | $9.0M | $8.4M |
| 2026-05-07 | -0.10 | -0.06 | $5.6M | $14.4M |
| 2026-08-06 | -0.12 | -0.05 | $4.7M | $13.4M |
| 2026-10-30 | -0.13 | -0.12 | $3.5M | $4.0M |
| 2027-03-03Upcoming | -0.12 | — | $5.2M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.